Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.
Adcirca is a registered trademark of Eli Lilly and Company.
UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months Ended December 31,Year Ended December 31,2010200920102009Revenues:Net product sales
166,477108,923603,831369,848Operating expenses:Research and development
62,25541,032166,761122,188Selling, general and administrative
74,99856,577199,600176,338Cost of product sales
18,53612,23367,71640,890Cost of service sales
1,6371,2635,7494,431Total operating expenses
157,426111,105439,826343,847(Loss) income from operations
9,051(2,182)164,00526,001Other income (expense):Interest income
(5,459)(3,659)(19,714)(12,875)Equity loss in affiliate
314145769636Total other (expense) income, net
(4,546)(2,551)(16,166)(7,234) Income (loss) before income tax
4,505(4,733)147,83918,767Income tax benefit (expense)
5,0391,403(41,923)695Net income (loss)
19,462Net income (loss) per common share:Basic
0.35Weighted average number of common shares outstanding:Basic
61,71553,92659,51656,133SELECTED CONSOLIDATED BALANCE SHEET DATA(In thousands)December 31,20102009Cash, cash equivalents and marketable securities (excluding restricted amounts of $5,122 and $39,976, respectively)
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved